Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness of Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children: a Randomized, Double-blind Placebo Controlled Trial

Next Previous
Trial Profile

Effectiveness of Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children: a Randomized, Double-blind Placebo Controlled Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lactobacillus reuteri (Primary)
  • Indications Diarrhoea
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Nov 2015 Primary endpoint (incidence of nosocomial diarrhoea) has not been met, according to results published in the Pediatric Infectious Disease Journal.
    • 06 Nov 2015 Results published in the Pediatric Infectious Disease Journal
    • 17 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top